U.S. Markets closed

InterMune Esbriet has become standard in seven EU countries, says JMP Securities

After attending a European Respiratory Society meeting, JMP Securities reports that the company's Esbriet drug has become standard of care for mild-moderate patients in seven European countries where it has been approved. The firm expects Esbriet to generate strong sales of $36M in 2H13 and it reiterates an Outperform rating on the stock.